InterLeukin-7 to Improve Clinical Outcomes in Lymphopenic pAtients With COVID-19 Infection ( ILIAD-7-US-I )

PHASE2TerminatedINTERVENTIONAL
Enrollment

26

Participants

Timeline

Start Date

September 15, 2020

Primary Completion Date

March 30, 2022

Study Completion Date

March 30, 2022

Conditions
COVID-19Lymphocytopenia
Interventions
DRUG

CYT107

IM administration at 10μg/kg twice a week for three weeks and up to 7 administrations according to Hospital length of stay

DRUG

Placebo

IM administration at 10μg/kg twice a week for three weeks and up to 7 administrations according to Hospital length of stay

Trial Locations (5)

11794

Stony Brook Medicine, Stony Brook

32608

University of Florida College of Medicine, Gainesville

44195

Cleveland Clinic Lerner College of Medicine, Cleveland

63131

Missouri Baptist Medical Center, St Louis

08901

Rutgers Health, New Brunswick

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Washington University School of Medicine

OTHER

collaborator

Amarex Clinical Research

OTHER

lead

Revimmune

INDUSTRY